Jeffrey Alan Jones Sells 4,582 Shares of Cullinan Therapeutics (NASDAQ:CGEM) Stock

Cullinan Therapeutics, Inc. (NASDAQ:CGEM) insider Jeffrey Alan Jones sold 4,582 shares of the business’s stock in a transaction that occurred on Tuesday, February 24th. The stock was sold at an average price of $14.47, for a total transaction of $66,301.54. Following the completion of the transaction, the insider directly owned 159,968 shares of the company’s stock, valued at approximately $2,314,736.96. This represents a 2.78% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.

Jeffrey Alan Jones also recently made the following trade(s):

• On Friday, February 20th, Jeffrey Alan Jones sold 4,982 shares of Cullinan Therapeutics stock. The shares were sold at an average price of $13.62, for a total transaction of $67,854.84.
• On Thursday, December 18th, Jeffrey Alan Jones sold 4,632 shares of Cullinan Therapeutics stock. The stock was sold at an average price of $9.67, for a total transaction of $44,791.44.

Cullinan Therapeutics Stock Up 5.9%

NASDAQ CGEM opened at $15.21 on Friday. The stock’s 50-day simple moving average is $11.61 and its two-hundred day simple moving average is $9.35. Cullinan Therapeutics, Inc. has a twelve month low of $5.68 and a twelve month high of $15.23. The company has a market capitalization of $898.61 million, a price-to-earnings ratio of -4.60 and a beta of -0.09.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in the company. Dynamic Technology Lab Private Ltd purchased a new stake in Cullinan Therapeutics during the 1st quarter valued at $163,000. Jane Street Group LLC raised its stake in shares of Cullinan Therapeutics by 145.9% during the first quarter. Jane Street Group LLC now owns 34,396 shares of the company’s stock valued at $260,000 after acquiring an additional 109,413 shares during the last quarter. Acadian Asset Management LLC purchased a new stake in shares of Cullinan Therapeutics during the first quarter worth about $618,000. Y Intercept Hong Kong Ltd purchased a new stake in shares of Cullinan Therapeutics during the second quarter worth about $84,000. Finally, Corton Capital Inc. grew its stake in shares of Cullinan Therapeutics by 28.9% in the second quarter. Corton Capital Inc. now owns 21,712 shares of the company’s stock worth $163,000 after purchasing an additional 4,870 shares during the last quarter. 86.31% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several analysts have issued reports on CGEM shares. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Cullinan Therapeutics in a research note on Monday, December 29th. Morgan Stanley restated an “overweight” rating and issued a $30.00 price objective on shares of Cullinan Therapeutics in a report on Thursday, January 8th. New Street Research set a $26.00 target price on shares of Cullinan Therapeutics in a report on Thursday, November 20th. Citigroup assumed coverage on shares of Cullinan Therapeutics in a research report on Tuesday, February 17th. They issued a “buy” rating and a $33.00 target price on the stock. Finally, Guggenheim initiated coverage on shares of Cullinan Therapeutics in a research note on Monday, February 2nd. They issued a “buy” rating and a $30.00 price target for the company. Eight research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $29.33.

Cullinan Therapeutics News Roundup

Here are the key news stories impacting Cullinan Therapeutics this week:

• Positive Sentiment: Near-zero reported short interest reduces potential forced selling and can limit downside pressure, supporting the stock’s move higher. Short Interest Report
• Positive Sentiment: Analyst coverage is tilted positive: several firms (Guggenheim, Citi, HC Wainwright) carry Buy ratings and materially higher price targets than the current quote, creating an upside narrative that can attract buyers. Analyst Coverage
• Positive Sentiment: Institutional investors increased positions in Q4 (Invesco, Virtus, Susquehanna and others reported larger stakes), which can provide buying support and signal conviction from larger market participants. Institutional Activity
• Neutral Sentiment: Market context: broader risk-on/risk-off swings (crypto weakness noted in recent headlines) can affect small-cap biotechs indiscriminately; this is a macro factor rather than company-specific news. Macro/Crypto Headline
• Neutral Sentiment: Some shops have trimmed ratings recently (a few downgrades), creating dispersion in expectations—this can increase volatility but does not decisively change the bullish analyst narrative. Analyst Notes
• Negative Sentiment: Multiple senior insiders sold sizable blocks on Feb. 24–25, including CEO Nadim Ahmed (13,515 shares) and other executives—clustered insider sales can be perceived as insider monetization and pressure sentiment. CEO Sale Filing
• Negative Sentiment: Director/executive Jennifer Michaelson executed multiple recent sales (Feb. 23–25 series of transactions), further trimming insider holdings and amplifying concerns about insider cash-outs. Insider Trades Summary

About Cullinan Therapeutics

Cullinan Therapeutics, Inc, a biopharmaceutical company, focuses on developing oncology therapies for cancer patients in the United States. The company's lead program comprises CLN-619, a monoclonal antibody that is in Phase I clinical trial for the treatment of solid tumors. Its development portfolio also includes CLN-049, a humanized bispecific antibody that is in Phase I clinical trial for the treatment of acute myeloid leukemia or myelodysplastic syndrome; CLN-418, a human bispecific immune activator that is in Phase 1 clinical trial for the treatment of multiple solid tumors; and Zipalertinib, a bioavailable small-molecule for treating patients with non-small cell lung cancer.